Skip to main content
MGTX logo

MGTX

MeiraGTx Holdings plc
$13.89 -0.03 (-0.22%) At close · Jul 6
Market Cap
$1.29B
Shares
92,609,516

Price & Indicators

20d MA 50d MA 200d MA Earnings Filing Insider Congress Investor day
Close$13.89 Open$13.83 Day$13.83–14.42 52W$6.62–14.42 Avg vol 30d1.0M Short int5.5M · 6.0% float · 9.2d Short vol55% Last earningsMay 14, 2026 DataJan 2020–Jul 2026 Filing10-Q · May 14
Equibles Rating blended score · not investment advice
Overall
Buy
Technical · trend & momentum Buy
50 / 200-day cross no cross
+ Price vs 200-day avg +60% above
+ Price vs 50-day avg +36% above
RSI (14) 74 · overbought
+ MACD trend positive
+ 52-week position 93% · near high
Sentiment · smart money Neutral
Trend (MA cross) 50d $10 › 200d $9 — 50d above 200d
+ Institutional flow 1 of 132 funds reported for Jun 30 · net +82 sh shares
Insider flow Net -$1.1M over 90 days · 100% sells
Short interest 5.99% of float · ▲ +2.9% MoM · 9.2 days cover
Volume signal Volume near normal
+ Institution breadth 132 holders — near 3-yr high, broad support
Fundamentals Excellent
+ Revenue growth +145% Y/Y
+ EPS growth +33% Y/Y
Free cash flow $-50.2M
+ Buyback $18.2M authorized
+ Balance sheet net cash $65.9M

Blended from price, positioning & fundamentals · daily-close · not investment advice.

Up next
Next earnings call
Aug 14, 2026 Est · unconfirmed · in 5 wks
FQ3-26 quarter ends
~Sep 30, 2026 Est
filed May 14, 2026

Technicals

trend & momentum for long-term holders Buy
1 · 1 · 4
50 / 200-day cross
no cross Neutral
Price vs 200-day avg
+60% above Bullish
Price vs 50-day avg
+36% above Bullish
RSI (14)
74 · overbought Bearish
MACD trend
positive Bullish
52-week position
93% · near high Bullish
Market signals — smart money & positioning
Mixed
Trend (MA cross) No cross
50d $10 › 200d $9 — 50d above 200d
Institutional flow Accumulating
1 of 132 funds reported for Jun 30 · net +82 sh shares
Insider flow Distributing
Net -$1.1M over 90 days · 100% sells
Short interest Rising
5.99% of float · ▲ +2.9% MoM · 9.2 days cover
Volume signal Normal
Volume near normal
Institution breadth Multi-yr high
132 holders — near 3-yr high, broad support
Price context
position in its 52-week range
52-wk low $7 Now $14 · 93% 52-wk high $14
vs 200-day avg +60% vs 50-day avg +36%

Illustrative technical + ownership context — a signal mix, not investment advice.

Versus peers

Biotechnology — same industry group
Open screener →
Company Mkt cap YTD Rev growth Y/Y P/E Short % shares
MGTX
MeiraGTx Holdings plc
this stock
$1.29B +74.7% +144.6% 6.0%
AKTX
Akari Therapeutics Plc
$998.08B -5.7% 0.0%
ONC
BeOne Medicines Ltd.
$488.96B +1.9% +22179.2% 957.1 0.1%
VRTX
Vertex Pharmaceuticals Inc / Ma
$134.41B +16.8% +46.2% 31.4 1.8%
REGN
Regeneron Pharmaceuticals, Inc.
$69.33B -15.7% +20.8% 16.1 3.2%

Peers by industry group · P/E from as-reported trailing EPS · short % is of shares outstanding

At a glance

key data from every section
Ownership
Institutional Holders Accumulating
Holders
132
% held
72.4%
Reported
1 of 132
Top holder
Sanofi
Held Float
View
Held by Funds
Fund positions
35
View
Short & Settlement
Short Interest Rising
Shares short
5.5M
Days to cover
9.2d
Change
+156.4K sh
View
Short Volume
Short vol %
55%
As of
Jul 6, 2026
Short Total
View
Fails to Deliver
FTD shares
3.4K
Value
$31.1K
As of
Jun 10, 2026
View
Off-Exchange
Off-exchange %
42.0%
Week of
May 4, 2026
Off-exch Lit
View
Smart Money
Insider Trades Net selling
Net (90d)
-$1.1M
Buyers / Sellers
0 / 2
Buyers Sellers
View
Financials
Financials
Revenue (FY)
$81.4M
Net income (FY)
$-114.2M
EPS diluted
$-1.42
View
Buybacks
Authorized
$18.2M
View
Filings
SEC Filings
Latest
8-K
Filed
Jun 15, 2026
This year
11
View
Proposed Sales
Value
$568.5K
Shares
62.0K
Filed
May 19, 2026
View
Earnings & Events
Earnings Calls
Last call
Jun 4, 2026
View

Performance

5D 20D 120D MTD YTD
MGTX +14.7% +45.1% +87.5% +2.8% +74.7%
SPY +3.1% -0.8% +8.2% +0.6% +10.2%
vs SPY +11.6% +45.9% +79.2% +2.2% +64.6%

Capital returns

Buyback program · as of Dec 31, 2025
Authorized
$18.20M
Spent (derived)
Remaining

Dividends per share over the trailing 365 days by ex-date · buyback figures as last reported in SEC filings ("spent" derived as authorized − remaining; when several programs run concurrently, authorized is their combined total per the newest filing) · components shown separately — trailing-year buyback spend isn't tracked, so no combined shareholder yield is derived.

Key facts CIK 1735438 CUSIP G59665102 13F (30d) 1 filings 1 filers Visit website Investor relations